These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9044028)

  • 1. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
    J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
    Burgess DS; Nathisuwan S
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):35-41. PubMed ID: 12376029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA; Isenberg HD; France KA; Jenkins SG
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
    García-Rodríguez JA; Trujillano I;
    Rev Esp Quimioter; 2002 Jun; 15(2):169-75. PubMed ID: 12582446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
    Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone.
    MacGowan AP; Wootton M; Hedges AJ; Bowker KE; Holt HA; Reeves DS
    J Antimicrob Chemother; 1996 Aug; 38(2):193-203. PubMed ID: 8877533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group].
    Gobernado M; Bouza E; Perea E; Alvarez-Bravo J; García Rodríguez JA
    Rev Esp Quimioter; 1998 Jun; 11(2):139-46. PubMed ID: 9795299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
    Strenkoski-Nix LC; Forrest A; Schentag JJ; Nix DE
    J Clin Pharmacol; 1998 Nov; 38(11):1063-71. PubMed ID: 9824789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
    Reeves DS; Holt HA; Bywater MJ; MacGowan AP
    J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.